RICHMOND, Calif., Oct. 1, 2015 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (OTCQB:EKSO), a robotic exoskeleton company, today announced the appointment of industry veteran Ruediger Hausherr to meet the needs of its expanding European markets.
"I am excited to help Ekso Bionics realize its potential in Europe, Middle East and Africa," said Mr. Hausherr. "We are an innovative company and well-positioned for significant growth in Europe. I believe we can further strengthen the continued expansion of our healthcare business and address unmet market needs by offering our innovative rehabilitation solutions. Our proprietary SmartAssist™ software1 for example, is able to uniquely adapt to the individual and track patient sessions to optimize progression and support early mobility."
Mr. Hausherr has over 20 years experience bringing novel new therapies to market in executive leadership positions in the Orthopedic field; including having served as CEO / shareholder for ORMED GmbH, which is now a DJO Global company, a prominent manufacturer of orthotic and rehabilitation products. He also currently serves as Board member for several healthcare companies worldwide, contributing to his broad base of industry know-how and market knowledge.
"We are proud to expand our global business with the addition of Ruediger Hausherr, who brings extensive knowledge of the rehabilitation segment as well as of the European healthcare market. We will greatly benefit from his strategic vision, leadership and proven track record for developing and delivering value in our target markets," adds Thomas Looby, president and chief commercial officer at Ekso Bionics.
To service the increase in clinical demand for its medical exoskeleton (Ekso GT™), Ekso Bionics has also brought on board Mr. Marco Sauer as Sales Manager and Mr. Sebastian Stallasch as Clinical Specialist Therapist. Mr. Sauer will be responsible for driving sales in German-speaking countries and Mr. Stallasch will be responsible for therapeutic evaluation of potential patients and training physical therapists on the Ekso GT as part of the Company's expansion efforts.
About Ekso Bionics
Since 2005, Ekso Bionics has been pioneering the field of robotic exoskeletons, or wearable robots, to augment human strength, endurance and mobility. The company's first commercially available product called Ekso has helped thousands of people living with paralysis take millions of steps not otherwise possible. By designing and creating some of the most forward-thinking and innovative solutions for people looking to augment human capabilities, Ekso Bionics is helping people rethink current physical limitations and achieve the remarkable.
Ekso Bionics is headquartered in Richmond, CA and is listed on the OTC QB under the symbol EKSO. www.eksobionics.com
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Forward-looking statements may include, without limitation, statements regarding (i) the plans and objectives of management for future operations, including plans or objectives relating to the design, development and commercialization of human exoskeletons, (ii) a projection of financial results, financial condition, capital expenditures, capital structure or other financial items, (iii) the Company's future financial performance and (iv) the assumptions underlying or relating to any statement described in points (i), (ii) or (iii) above. Such forward-looking statements are not meant to predict or guarantee actual results, performance, events or circumstances and may not be realized because they are based upon the Company's current projections, plans, objectives, beliefs, expectations, estimates and assumptions and are subject to a number of risks and uncertainties and other influences, many of which the Company has no control over. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. Factors that may influence or contribute to the inaccuracy of the forward-looking statements or cause actual results to differ materially from expected or desired results may include, without limitation, the Company's inability to obtain adequate financing to fund the Company's operations and necessary to develop or enhance our technology, the significant length of time and resources associated with the development of the Company's products, the Company's failure to achieve broad market acceptance of the Company's products, the failure of our sales and marketing organization or partners to market our products effectively, adverse results in future clinical studies of the Company's medical device products, the failure to obtain or maintain patent protection for the Company's technology, failure to obtain or maintain regulatory approval to market the Company's medical devices, lack of product diversification, existing or increased competition, and the Company's failure to implement the Company's business plans or strategies. These and other factors are identified and described in more detail in the Company's filings with the SEC. The Company does not undertake to update these forward-looking statements.
1 This generation of Variable Assist software is only available outside the US.
CONTACT: Media Contact: Heidi Darling, Director of Marketing Communications Phone: 510-984-1761 x317 E-mail: firstname.lastname@example.org Investor Contact: Chad Rubin, Senior Vice President Phone: 646-378-2947 E-mail: email@example.com